{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-206255","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.054497+00:00","generated_at":"2026-06-12T01:35:39.502015+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Soleno completes enrollment in PWS Study C602; Q2 net loss $8.5M","bullets":["Completed enrollment in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.","Top-line data expected around end of Q3 2023; could support NDA submission to FDA.","Received $10M from SPA warrant exercise; cash and equivalents $19.4M as of June 30, 2023.","Net loss for Q2 2023 was $8.5M ($0.81 per share) vs $6.7M ($0.72 per share) in Q2 2022.","R&D expenses $5.1M in Q2 2023, up from $3.7M year-over-year due to clinical progress."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-206255","json":"https://secwatch.observer/filing/0001193125-23-206255.json","markdown":"https://secwatch.observer/filing/0001193125-23-206255.md","text":"https://secwatch.observer/filing/0001193125-23-206255.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523206255/0001193125-23-206255-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523206255/d452584d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:35:39.502015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af23879ad17a3d74a87e9326150f1ea67050ce76","claim":"SOLENO THERAPEUTICS INC reported the second quarter ended June 30, 2023 results: net income $8.5 million, EPS $0.81.","evidence_excerpt":"Net loss for the three and six months ended June 30, 2023, was $8.5 million and $16.8 million, or a net loss of $0.81 and $1.69 per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523206255/0001193125-23-206255-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$8.5 million"},{"label":"EPS","value":"$0.81"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}